Lichen planus pemphigoides after pembrolizumab immunotherapy in an older man.

[1]  Douglas B. Johnson,et al.  Cutaneous adverse events caused by immune checkpoint inhibitors. , 2021, Journal of the American Academy of Dermatology.

[2]  T. Sugihara,et al.  Case of lichen planus pemphigoides after pembrolizumab therapy for advanced urothelial carcinoma , 2020, The Journal of dermatology.

[3]  Douglas B. Johnson,et al.  Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.

[4]  M. Mizuashi,et al.  Lichen planus pemphigoides developing from patient with non‐small‐cell lung cancer treated with nivolumab , 2019, The Journal of dermatology.

[5]  D. Speiser,et al.  Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. , 2019, JAMA oncology.

[6]  W. Horninger,et al.  Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - A case report , 2018, Urology case reports.

[7]  V. Sibaud.  Dermatologic Reactions to Immune Checkpoint Inhibitors , 2018, American Journal of Clinical Dermatology.

[8]  C. Loquai,et al.  Pembrolizumab‐induced lichen planus pemphigoides in a patient with metastatic melanoma , 2017, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[9]  M. Tetzlaff,et al.  Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features. , 2017, The American Journal of dermatopathology.

[10]  J. Wolchok,et al.  Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. , 2016, European journal of cancer.